BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18076562)

  • 1. Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
    Vega JC; Sanchez BF; Montero LM; Montaña R; Del Pilar Mahecha M; Dueñes B; Baron AR; Reithinger R
    Trop Med Int Health; 2007 Dec; 12(12):1540-4. PubMed ID: 18076562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting.
    Vega JC; Sanchez BF; Montero LM; Montaña R; Mahecha Mdel P; Dueñes B; Baron AR; Reithinger R
    Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):703-6. PubMed ID: 19059616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia.
    Cardona-Arias JA; López-Carvajal L; Tamayo-Plata MP; Vélez ID
    BMC Public Health; 2018 Jan; 18(1):185. PubMed ID: 29378537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.
    Soto J; Toledo J; Vega J; Berman J
    Am J Trop Med Hyg; 2005 Apr; 72(4):421-2. PubMed ID: 15827279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cutaneous leishmaniasis].
    Vion B
    Rev Med Suisse Romande; 1989 Jun; 109(6):443-9. PubMed ID: 2547241
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
    Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
    Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of Pediatric Visceral Leishmaniasis Care in Morocco.
    Tachfouti N; Najdi A; Alonso S; Sicuri E; Laamrani El Idrissi A; Nejjari C; Picado A
    PLoS One; 2016; 11(6):e0155482. PubMed ID: 27257808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
    Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous leishmaniasis imported from Colombia to Northcentral Venezuela: implications for travel advice.
    Delgado O; Silva S; Coraspe V; Rivas MA; Rodriguez-Morales AJ; Navarro P; Franco-Paredes C
    Travel Med Infect Dis; 2008 Nov; 6(6):376-9. PubMed ID: 18984484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
    Olliaro P; Darley S; Laxminarayan R; Sundar S
    Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral leishmaniasis in clinical practice.
    Davidson RN
    J Infect; 1999 Sep; 39(2):112-6. PubMed ID: 10609527
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of cutaneous leishmaniasis].
    Lambert D; Mambre B
    Ann Dermatol Venereol; 1988; 115(5):641-3. PubMed ID: 3058010
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current situation and future of antileishmanial therapy in Colombia].
    Soto J; Soto P
    Biomedica; 2006 Oct; 26 Suppl 1():194-206. PubMed ID: 17361855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.
    Soto J; Valda-Rodriquez L; Toledo J; Vera-Navarro L; Luz M; Monasterios-Torrico H; Vega J; Berman J
    Am J Trop Med Hyg; 2004 Nov; 71(5):577-81. PubMed ID: 15569787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
    Sadeghian G; Nilfroushzadeh MA; Iraji F
    Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency setting.
    Reithinger R; Coleman PG
    BMC Infect Dis; 2007 Jan; 7():3. PubMed ID: 17263879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of meglumine antimoniate in canine leishmaniasis.
    Lamothe J
    Vet Rec; 2004 Mar; 154(12):378. PubMed ID: 15074332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.